What is the dosage of cyclosporine for a 12-month-old patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cyclosporine Dosing for a 12-Month-Old Child

For a 12-month-old child with nephrotic syndrome, the recommended starting dose of cyclosporine is 4-5 mg/kg/day divided into two doses, with target trough levels of 60-150 ng/ml. 1

Initial Dosing Recommendations

  • For children with nephrotic syndrome, cyclosporine should be started at 4-5 mg/kg/day divided into two equal doses (morning and evening) 1
  • The dose should be given on an empty stomach or before meals for optimal absorption 1
  • For steroid-dependent nephrotic syndrome, cyclosporine should be commenced after achieving complete remission of proteinuria with prednisone 1
  • In steroid-resistant cases, cyclosporine may be considered with concomitant prednisone for at least 6 months 1

Monitoring and Dose Adjustments

  • Monitor cyclosporine trough levels during therapy to limit toxicity, with target 12-hour trough levels of 60-150 ng/ml 1
  • Check serum creatinine and blood pressure at fortnightly intervals for the first 2 months, then monthly thereafter 1
  • Monitor complete blood count, liver function tests, electrolytes, and lipid profile regularly 1
  • If serum creatinine increases >30% above baseline, reduce the dose by 25-50% 2
  • If no response occurs after 6 months of treatment (minimum 50% reduction in baseline proteinuria), consider alternative treatments 1

Duration of Treatment

  • Cyclosporine should be continued for at least 12 months as most children will relapse upon discontinuation 1
  • Following complete remission, cyclosporine should be slowly tapered (by 0.5 mg/kg/month) to the minimum effective dose 1
  • Maintenance therapy may be required for 1-2 years 1

Potential Side Effects and Management

  • Common side effects include hypertension (monitor blood pressure regularly), gum hypertrophy, hirsutism, and hypertrichosis 1
  • Nephrotoxicity can occur, especially with prolonged treatment (>2 years) 1
  • Consider repeat renal biopsies in children receiving long-term (>2 years) cyclosporine therapy 1
  • Most side effects are reversible upon dose reduction or drug discontinuation 1, 3

Special Considerations for Infants

  • Younger children (≤9 years) not on voriconazole may require higher initial doses of cyclosporine to reach therapeutic levels 4
  • Careful monitoring is particularly important in infants due to their developing renal function 1
  • The microemulsion formulation of cyclosporine is preferred for more consistent absorption 5

Treatment Algorithm

  1. Confirm diagnosis of nephrotic syndrome requiring cyclosporine therapy 1
  2. Start at 4-5 mg/kg/day divided into two doses 1
  3. Monitor trough levels (target: 60-150 ng/ml), serum creatinine, and blood pressure regularly 1
  4. Continue for at least 12 months if responding 1
  5. Taper slowly after complete remission to minimum effective dose 1
  6. Consider discontinuation after 1-2 years of stable remission 1

Remember that rapid deterioration of renal function may occur even after years of continuous treatment when cyclosporine is stopped, so careful monitoring during tapering is essential 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Aplastic Anemia with Cyclosporine and ATG

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Ciclosporin treatment in children with steroid-dependent nephrotic syndrome.

Pediatric nephrology (Berlin, Germany), 1990

Research

Optimizing cyclosporine A dose post allogeneic hematopoietic stem cell transplantation in paediatric cancer patients.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2024

Guideline

Cyclosporine Protocol for Acute Generalized Exanthematous Pustulosis (AGEP)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.